Evidence map›Paper›PMID 38227786›Full record

ArticleThe Journal of infectious diseases2024

Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study.

Irene A Abela, Anthony Hauser, Magdalena Schwarzmüller, Chloé Pasin, Katharina Kusejko, Selina Epp, Matthias Cavassini, Manuel Battegay, Andri Rauch, Alexandra Calmy and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Irene A AbelaDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.ORCID 0000-0002-5566-8628
Anthony HauserDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.ORCID 0000-0002-7221-1929
Magdalena SchwarzmüllerInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Chloé PasinDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Katharina KusejkoDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.ORCID 0000-0002-4638-1940
Selina EppInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Matthias CavassiniDivision of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland.ORCID 0000-0003-0933-7833
Manuel BattegayDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Andri RauchDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Alexandra CalmyLaboratory of Virology and Division of Infectious Diseases, Geneva University Hospital, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-1137-6826
Julia NotterDivision of Infectious Diseases, Cantonal Hospital St Gallen, St Gallen, Switzerland.
Enos BernasconiDivision of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland.ORCID 0000-0002-9724-8373
Christoph A FuxDepartment of Infectious Diseases, Kantonsspital Aarau, Aarau, Switzerland.
Karoline LeuzingerClinical Virology, University Hospital Basel, Basel, Switzerland.
Matthieu PerreauDivision of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Alban RametteInstitute for Infectious Diseases, University of Bern, Bern, Switzerland.
Jochen GottschalkBlood Transfusion Service Zurich, Zurich, Switzerland.
Eméry SchindlerBlood Transfusion Service Zurich, Zurich, Switzerland.
Alexander WepfInstitute of Laboratory Medicine, Cantonal Hospital Winterthur, Winterthur, Switzerland.
Maddalena MarconatoDepartment of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland.
Markus G ManzDepartment of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland.
Beat M FreyBlood Transfusion Service Zurich, Zurich, Switzerland.
Dominique L BraunDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Michael HuberInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0384-0000
Huldrych F GünthardDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Alexandra TrkolaInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-1013-876X
Roger D KouyosDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Swiss HIV Cohort Study

Funding

Gilead COVID-19 RFP Research Program IN-SW-983-6078Promedica FoundationSHCS Project 870SHCS Research FoundationSwiss National Science Foundation 31CA30_196906
6 · The paper itself

Abstract

backgroundFactors influencing susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain to be resolved. Using data from the Swiss HIV Cohort Study on 6270 people with human immunodeficiency virus (HIV) and serologic assessment for SARS-CoV-2 and circulating human coronavirus (HCoV) antibodies, we investigated the association of HIV-related and general parameters with SARS-CoV-2 infection.

methodsWe analyzed SARS-CoV-2 polymerase chain reaction test results, COVID-19-related hospitalizations, and deaths reported to the Swiss HIV Cohort Study between 1 January 2020 and 31 December 2021. Antibodies to SARS-CoV-2 and HCoVs were determined in prepandemic (2019) and pandemic (2020) biobanked plasma samples and compared with findings in HIV-negative individuals. We applied logistic regression, conditional logistic regression, and bayesian multivariate regression to identify determinants of SARS-CoV-2 infection and antibody responses to SARS-CoV-2 in people with HIV.

resultsNo HIV-1-related factors were associated with SARS-CoV-2 acquisition. High prepandemic HCoV antibodies were associated with a lower risk of subsequent SARS-CoV-2 infection and with higher SARS-CoV-2 antibody responses on infection. We observed a robust protective effect of smoking on SARS-CoV-2 infection risk (adjusted odds ratio, 0.46 [95% confidence interval, .38-.56]; P < .001), which occurred even in previous smokers and was highest for heavy smokers.

conclusionsOur findings of 2 independent protective factors, smoking and HCoV antibodies, both affecting the respiratory environment, underscore the importance of the local immune milieu in regulating susceptibility to SARS-CoV-2.

Indexed as

Antibodies, ViralCOVID-19HIV InfectionsSARS-CoV-2AdultAgedCohort StudiesDisease SusceptibilityFemaleHumansMaleMiddle AgedRisk FactorsSwitzerlandAntibodies, Viralendemic human coronavirusesHIVpreexisting immunitySARS-CoV-2smoking

Identifiers

PMID38227786
PMCPMC11326820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.